Journal
NEURO-ONCOLOGY
Volume 20, Issue 6, Pages 743-752Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nox191
Keywords
angiogenesis; EGFR; glioblastoma; invasion, targeted therapy; tumor heterogeneity
Categories
Funding
- Research Council of Norway
- Norwegian Cancer Society
- Helse Vest
- Haukeland University Hospital
- University of Bergen
- K. G. Jebsen Research Foundation
- Italian Association for Cancer Research [AIRC 2013 IG 14042]
Ask authors/readers for more resources
Patients with glioblastoma (GBM) have a universally poor prognosis and are in urgent need of effective treatment strategies. Recent advances in sequencing techniques unraveled the complete genomic landscape of GBMs and revealed profound heterogeneity of individual tumors even at the single cell level. Genomic profiling has detected epidermal growth factor receptor (EGFR) gene alterations in more than half of GBMs. Major genetic events include amplification and mutation of EGFR. Yet, treatment strategies targeting EGFR have thus far failed in clinical trials. In this review, we discuss the clonal and functional heterogeneity of EGFRs in GBM development and critically reassess the potential of EGFRs as therapeutic targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available